Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307401 | 0.91 | PTPN1 (0.51) | PTPN1MDM4TP53MEN1ALDH1A1 | |
| SCHEMBL3728097 | 0.91 | PTPN1 (0.51) | PTPN1MDM4TP53MEN1ALDH1A1 | |
| SCHEMBL3725675 | 0.91 | PTPN1 (0.51) | PTPN1MDM4TP53MEN1ALDH1A1 | |
| SCHEMBL28741502 | 0.89 | MDM4 (0.52) | MDM4TP53CASP3 | |
| SCHEMBL28741504 | 0.89 | MDM4 (0.52) | MDM4TP53CASP3 | |
| SCHEMBL12568250 | 0.88 | CTSS (0.52) | PTPN1MDM4TP53CASP3 | |
| SCHEMBL12059890 | 0.88 | MDM4 (0.51) | PTPN1MDM4TP53CASP3 | |
| SCHEMBL12568249 | 0.88 | CTSS (0.52) | PTPN1MDM4TP53CASP3 | |
| SCHEMBL31097650 | 0.88 | MDM4 (0.51) | PTPN1MDM4TP53CASP3 | |
| SCHEMBL25266952 | 0.88 | PTPN1 (0.53) | HDAC8PTPN1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | FOLR1, FOLR2, FOLH1 | HDAC8 2835/4885PTPN1 3004/4885MDM4 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.